Now Offering KYBELLA, the First Injectable Drug for Submental Fullness, or Double Chin
KYBELLA™ (deoxycholic acid) injection, the first and only FDA-approved injectable drug available that contours and improves the appearance of moderate to severe submental fullness, sometimes referred to as a “double chin,” is now available in Baltimore. Submental fullness is a common, yet under-treated aesthetic condition that is often resistant to diet and exercise alone and influenced by several factors, including aging, genetics and weight gain.
We are excited to be one of the first plastic surgery offices in Baltimore to be able to offer KYBELLA™ to patients. We have been trained on the proper technique for administering the treatment for the safety of our patients.
Each in-office treatment session with KYBELLA™ is typically 15-20 minutes. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved with KYBELLA™, re-treatment is not expected.
With this nonsurgical treatment, many patients experience visible results in two to four treatment sessions spaced at least one month apart. Up to six treatments may be administered. Treatment with KYBELLA™ is customized by CHG Plastic surgery to the patient’s aesthetic goals for an improved chin profile.
The most common side effects are swelling, bruising, pain, numbness, redness and formation of areas of hardness in the treatment area. In clinical trials, the incidence and severity of most side effects decreased with subsequent KYBELLA™ treatments. KYBELLA™ can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness.
KYBELLA™ has been the focus of a global clinical development program involving over 20 clinical studies with more than 2,600 patients worldwide, of which 1,600 have been treated with KYBELLA™